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We hypothesized that oxidative stress may contribute to the development of hypertrophy 2 
observed in mice with cardiac specific ablation of the insulin sensitive glucose 3 
transporter 4 gene (GLUT4, G4H-/-). Measurements of oxidized glutathione (GSSG) in 4 
isolated mitochondria and whole heart homogenates were increased resulting in a lower 5 
ratio of reduced glutathione (GSH) to GSSG. Membrane translocation of the p67phox 6 
subunit of cardiac NOX2 was markedly increased in G4H-/- mice, suggesting elevated 7 
activity. To determine if oxidative stress was contributing to cardiac hypertrophy, 4-week 8 
old Con and G4H-/- mice were treated with either tempol (T, 1mM, drinking water), a 9 
whole cell antioxidant, or Mn(III)tetrakis(4-Benzoic acid) porphyrin chloride (MnTBAP, 10 10 
mg/kg, ip), a mitochondrial targeted antioxidant, for 28d. Tempol attenuated cardiac 11 
hypertrophy in G4H-/- mice (heart:tibia, Con 6.82±0.35, G4H-/- 8.83±0.34, Con+T 12 
6.82±0.46, G4H-/-+T 7.57±0.3), without changing GSH:GSSG, GPX4, or membrane 13 
translocation of the p67phox.  Tempol did not modify phosphorylation of glycogen 14 
synthase kinase (GSK) 3β or thioredoxin-2. In contrast, MnTBAP lowered mitochondrial 15 
GSSG, improved GSH:GSSG, but did not prevent hypertrophy; indicating that 16 
mitochondrial oxidative stress may not be critical for hypertrophy in this model. The 17 
ability of tempol to attenuate cardiac hypertrophy suggests that a cytosolic source of 18 
reactive oxygen species, likely NOX2, may contribute to the hypertrophic phenotype in 19 
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Epidemiological and clinical studies report that diabetes is associated with 2 
cardiac hypertrophy after adjusting for underlying coronary artery disease, ischemia or 3 
hypertension [1-3]. Cardiac hypertrophy alone is an independent risk factor for 4 
cardiovascular morbidity and mortality [4]. One commonly reported feature of the 5 
diabetic heart is an increase in reactive oxidative species (ROS) [5-7]. Major sources of 6 
ROS in the heart are NADPH oxidase and/or mitochondrial oxidative phosphorylation [8]. 7 
ROS are routinely removed by cellular antioxidants including superoxide dismutase 8 
(SOD, consisting of two isoforms; a mitochondrial Mn-SOD and cytosolic Cu-Zn-SOD), 9 
catalase, and glutathione peroxidase [8].  The characteristic increase in fatty acid β-10 
oxidation (FAO) in diabetes coupled with increased cellular oxygen demand and 11 
mitochondrial dysfunction [9] increases the potential for ROS generation. Oxidative 12 
stress has been reported to play a critical role in cardiac hypertrophy [10, 11]. Similarly, 13 
impairment of endogenous antioxidant defenses through inhibition of thioredoxin results 14 
in cardiac hypertrophy [12], while the loss of superoxide dismutase (SOD) exacerbates 15 
hypertrophy in response to pressure overload [13].  16 
We previously established a mouse model with cardiac specific deletion of the 17 
glucose transporter 4 gene (GLUT4, G4H-/-) to study the effect of impaired cardiac 18 
glucose uptake on the ensuing cardiac phenotype [14]. Initial characterization revealed 19 
that cardiomyocyte loss of both GLUT4 mRNA and protein resulted in moderate cardiac 20 
hypertrophy without fibrosis [14]. This change in individual cardiomyocyte size develops 21 
by eight weeks of age in the absence of hyperinsulinemia, hyperglycemia or changes in 22 
serum concentrations of fatty acid, lactate, amino acids or ketones [14].  23 
A recent study using an independently-generated murine model of GLUT4 24 
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and fat, suggested that oxidative stress plays a role in cardiac hypertrophy, as treating 1 
adult mice (~150 d old) with tempol (a membrane permeable antioxidant) reversed 2 
cardiac hypertrophy [15]. Although tempol treatment in this study was associated with 3 
reduced mRNAs of NOX1 and gp91phox, measured NADPH Oxidase activities were not 4 
altered in GLUT4 deficient hearts prior to and after tempol treatment.  Thus the precise 5 
source of ROS in GLUT4 deficient hearts is not well characterized and the potential role 6 
that mitochondrial oxidative stress may play in stimulating cardiac hypertrophy in these 7 
hearts is incompletely understood. Moreover, the role of oxidative stress in cardiac 8 
hypertrophy in GLUT4 deficient hearts that are not confounded by systemic insulin 9 
resistance or reduced expression of GLUT4 in other tissues remains to be clarified. The 10 
contribution of mitochondria to ROS generation may be important in G4H-/- mice given 11 
the alterations in substrate utilization and FAO previously observed in insulin resistant 12 
hearts. Therefore, we hypothesized that reducing mitochondrial oxidative stress would 13 
prevent the development of cardiac hypertrophy in G4H-/- mice.  To test this hypothesis 14 
we first determined the degree to which young and adult G4H-/- mice have cardiac 15 
oxidative stress, and then compared the effects of treating mice with 2 unique 16 
antioxidants; tempol and Mn(III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP) 17 
on development of cardiac hypertrophy. Tempol is a whole cell antioxidant that has been 18 
shown to reduce markers of oxidative stress in membrane, cytosol, and mitochondrial 19 
compartments [16, 17], while MnTBAP is a mitochondrial-targeted superoxide 2 mimetic. 20 
We report here that G4H-/- mice show signs of mild oxidative stress, which likely stems 21 
from NOX2, a cytosolic source of reactive oxygen species (ROS). Furthermore, while 22 
treatment with the whole cell antioxidant tempol attenuates cardiac hypertrophy, the 23 
mitochondrial-targeted antioxidant, MnTBAP, does not. 24 
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Cardiac hypertrophy and markers of oxidative stress. 2 
Mixed gender cohorts were used for all studies. Body mass (g) and tibia lengths 3 
were similar between groups (Table 1). In agreement with previous studies that have 4 
characterized the cardiac phenotype of these G4H-/- mice [14, 18], heart mass was 5 
increased and cardiac hypertrophy was present in G4H-/- mice compared to Con at 25 6 
weeks of age but was not present at 5 weeks of age (Table 1). Multiple markers of 7 
oxidative stress were examined in hearts of 25-week old mice. Total ROS as determined 8 
by DCFDA assay in whole cardiac homogenates and malondialdehyde (MDA) were 9 
similar between Con and G4H-/- mice (Figure 1A, B).  In isolated mitochondria, hydrogen 10 
peroxide concentrations and aconitase activity were unchanged as well (Figure 1C, D). 11 
Cytosolic aconitase activity was not altered in G4H-/- compared to Con mice (Figure 1E). 12 
While concentrations of GSH (reduced glutathione) in whole cardiac homogenates was 13 
unchanged in G4H-/- mice, the amount of GSSG (oxidized glutathione) was significantly 14 
greater such that GSH:GSSG was lower in G4H-/- mice compared to Con (Figure 1F-H). 15 
In 5-week-old mice prior to the onset of cardiac hypertrophy, a similar pattern of 16 
increased GSSG leading to reduced GSH:GSSG ratios were observed (Table 1). 17 
Interestingly, at 8-weeks of age, the reduction in GSH:GSSG ratios were secondary to 18 
reduced GSH that was associated with a more modest increase in GSSG (Table 2). In 19 
isolated mitochondria an increase in GSSG and reduced GSH:GSSG ratios were 20 
observed in G4H-/- hearts (Table 3).  21 
 22 
Tempol Treatment 23 
Since increased cardiac oxidized glutathione concentrations preceded cardiac 24 
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phenotype in G4H-/- mice. To test this, the antioxidant tempol was administered as a 1 1 
mM solution in drinking water. Overall water consumption was unchanged among 2 
treated vs. untreated mice (data not shown). Body weight and tibia length were also 3 
unchanged during the 4-week treatment period (Table 2). Tempol prevented cardiac 4 
hypertrophy in G4H-/- mice as evidenced by similar heart weight and heart:tibia length in 5 
tempol treated G4H-/- mice vs. control mice (Table 2). GSH:GSSG was lower in all G4H-/- 6 
compared to all Con, and tempol treatment did not alter this ratio (Table 2).  7 
To assess if the changes in the GSH:GSSG ratio in G4H-/- hearts could be 8 
accounted for by upregulation of glutathione peroxidase (GPX) and/or downregulation of 9 
glutathione reductase (GR) we measured RNA and protein levels of these enzymes. 10 
There was no difference in either GR gene transcripts or protein in hearts of Con vs. 11 
G4H-/- mice (Figures 2a, 3a). There was also no change in gene expression of GPX4 12 
and GPX1 in hearts of G4H-/- mice vs. Con (Figure 2a). Protein expression of GPX4 in 13 
untreated G4H-/- mice was inconsistent between cohorts used for the tempol and 14 
MnTBAP studies. For example, in the tempol study GPX4 was greater in G4H-/- mice vs. 15 
Con, but in the MnTBAP cohort, where both G4H-/- and Con received daily intraperitoneal 16 
injections of saline, GPX4 was similar (Figure 3). Although there were minor changes in 17 
GPX4 expression levels in tempol-treated G4H-/-, protein levels were not modulated by 18 
tempol in control or G4H-/- mouse hearts, respectively.  Similarly, small changes in 19 
glutathione reductase protein, in the MnTBAP cohort are unlikely to account for the 20 
differences observed in GSH:GSSG ratios.  21 
NOX2 is a generator of cytosolic superoxide that is located on the cell 22 
membrane. Full activation of NOX2 requires assembly with p67phox (also known as 23 
NOXA1) and p47phox subunits before superoxide can be produced. Expression of the 24 
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similar among all groups (Figure 2a). The protein levels of p67phox subunit of NOX2 in 1 
cardiac membrane fractions were markedly greater in G4H-/- vs. Con, suggesting an 2 
increase in NOX2 activation. Protein levels of p67phox in the cytosol were unchanged 3 
(data not shown). The activation state of NOX2 remained unchanged in G4H-/-+T mice 4 
as the membrane localization of p67phox protein was similar to untreated G4H-/- (Figure 5 
4). Thioredoxin (TXN2) expression, a redox-active molecule that is found in cardiac 6 
mitochondria, was increased in G4H-/- mice vs. Con, but, similar between Con+T and 7 
G4H-/-+T (Figure 2a).  8 
The reduction in cardiac hypertrophy resulting from tempol treatment in G4H-/- 9 
mice was accompanied by the reduction of some, but not all of the classic genetic 10 
markers of hypertrophy. In G4H-/- mice α-MHC, brain naturetic peptide (BNP), SERCA2a, 11 
and SERCA2b were unchanged compared to Con, and were not further affected by 12 
tempol treatment (Figure 2b). In contrast to the present study, our original study 13 
characterizing G4H-/- mice found increases in BNP[14]. We believe that the most likely 14 
basis for this difference is that our previous work used only male mice aged 13-14 15 
weeks, and northern blots were employed to detect BNP expression, whereas the 16 
current study used a mixed cohort of 8-week old males and females, and real time PCR 17 
was used to detect transcripts. Expression of atrial naturetic factor (ANF), on the other 18 
hand, was increased in G4H-/- mice vs. Con. While there was a trend present (p=0.06) 19 
toward increased β-myosin heavy chain (MHC) between Con and G4H-/- mice, this was 20 
not statistically significant (Figure 2b). β-MHC expression was similar in tempol treated 21 
Con and G4H-/- mice (Figure 2b). Consistent with previous reports [14], GLUT1 22 
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Glycogen synthase kinase (GSK) 3β inactivation has been reported to play a role 1 
in other diabetic models of cardiac hypertrophy [19]. To determine if tempol reduced 2 
cardiac hypertrophy in G4H-/- mice through an oxidative stress independent mechanism, 3 
we measured phosphorylated -(p) GSK3β and total GSK3β in hearts of Con and G4H-/- 4 
mice. Our data indicated that the ratio of p-GSK3β to total GSK3β was unchanged 5 
between Con and G4H-/- mice, and that tempol did not affect GSK3β activation in either 6 
group (Figure 5). 7 
 8 
MnTBAP treatment. 9 
 Isolated mitochondria of G4H-/- mice had greater GSSG and reduced GSH:GSSG 10 
compared to control mice (Table 3). To determine if a mitochondrial oxidative stress was 11 
a contributor to cardiac hypertrophy in G4H-/- mice, we used the mitochondrial targeted 12 
antioxidant MnTBAP. A 4-week treatment with MnTBAP increased mitochondrial GSH in 13 
G4H-/- mice compared to saline treated G4H-/-. MnTBAP also lowered GSSG and 14 
increased GSH:GSSG in G4H-/- mice to levels similar to controls. However, this 15 
improvement in mitochondrial oxidative stress was not accompanied by a reduction in 16 
heart weight or cardiac hypertrophy (Table 3). These data indicate that while 17 
mitochondrial oxidative stress is present in G4H-/- mice, it is unlikely to be the basis for 18 
the development of cardiac hypertrophy. MntBAP treatment did not produce any change 19 
in mRNAs for GR, GPX1 or TXN2. There was also no effect of MnTBAP treatment on 20 
GPX4 protein and the small reduction in GR cannot account for changes in GSH:GSSG 21 
that was observed. 22 
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The major findings of this study are that G4H-/- mice have signs of low level 1 
oxidative stress in the heart since both whole cell homogenate and mitochondrial 2 
preparations had lower GSH:GSSG. The reduction in GSH:GSSG was seen in mice as 3 
young as 5 weeks old, prior to the presence of significant cardiac hypertrophy, 4 
suggesting a role for oxidative stress in the pathogenesis of hypertrophy. G4H-/- mice 5 
also had increased protein expression of p67phox. Treatment with a general membrane 6 
permeable antioxidant, tempol, prevented cardiac hypertrophy, while the mitochondrial-7 
targeted antioxidant, MnTBAP, did not affect development of hypertrophy. Tempol 8 
treatment did not reverse the membrane localization of p67phox and did not normalize 9 
GSH:GSSG, so the possibility remains that the impact of tempol on cardiac hypertrophy 10 
could be an off target effect that is unrelated to oxidative stress. However, the MnTBAP 11 
experiments presented in this study strongly suggest that mitochondrial oxidative stress 12 
is unlikely to play a role in cardiac hypertrophy in G4H-/- hearts.  13 
Our conclusion that G4H-/- mice have low-level oxidative stress is based on data 14 
indicating that there was no difference between many indicators of oxidative stress in 15 
Con vs. G4H-/- mice, whereas glutathione concentrations were consistently altered in 16 
G4H-/- mice. In agreement with our study, previous studies using rodents have also 17 
reported changes in glutathione ratio without alterations in other markers of oxidative 18 
stress, such as lipid peroxidation [20]. This suggests that the status of glutathione is a 19 
sensitive indicator of the redox state of the heart. Glutathione is a major antioxidant in 20 
the cell and it is well known that oxidative stress consumes reduced glutathione (GSH). 21 
Increases in oxidized cardiac glutathione are widely reported in rodents with 22 
hypertrophy, heart failure, and/or diabetes [21-24]. Changes in the ratio of oxidized 23 
versus reduced glutathione, could be secondary to differences in the expression or 24 
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in the concentration of proton donors or acceptors. GPX4 protein levels were actually 1 
lower and GR protein levels were unchanged between Con and G4H-/- mice. Thus 2 
enzyme levels cannot account for the differences observed, although changes in activity 3 
cannot be ruled out.  4 
This current study follows a previous report by Ritchie et al. that used a different 5 
model wherein cardiac specific GLUT4 deletion was superimposed upon reduced 6 
GLUT4 expression in all tissues [15]. There were several points of similarity between our 7 
study and the aforementioned one. Ritchie et al. reported that tempol reduced both 8 
cardiac hypertrophy without any change in NOX2 mediated superoxide production [15]. 9 
Similarly, we also found that tempol attenuated hypertrophy and that translocation of 10 
p67phox in G4H-/- mice was not affected. However, there are also several important 11 
differences between the experimental design and methods of the current study and the 12 
one by Ritchie et al. For example, 1) the G4H-/- mouse used in our study is a specific 13 
model of cardiac specific GLUT4 deletion, whereas the model used by Ritchie et al. has 14 
very low, but not completely deleted levels cardiac GLUT4 protein that is superimposed 15 
on whole body GLUT4 knockdown, 2) our model does not have insulin resistance, 16 
whereas the model used by Ritchie et al. does, 3) we examined a number of markers of 17 
oxidative stress in both cytosol and mitochondria, 4) we conducted additional 18 
experiments with another antioxidant (MnTBAP) to evaluate the potential contribution of 19 
mitochondrial-specific oxidative stress to the development of cardiac hypertrophy. The 20 
effectiveness of MnTBAP to reduce mitochondrial superoxide has been previously 21 
demonstrated in vitro and in vivo using oxygen-glucose depleted cortical cell cultures 22 
[25] and SOD2 null mice [26]. Furthermore, since mitochondria have a negative resting 23 
potential, it is thought that they can accumulate positively charged antioxidant 24 
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One of the aims of this study was to determine if the source of oxidative stress 1 
was mitochondrial or cytosolic in origin. General parameters of oxidative stress such as 2 
malondialdehyde levels, cytosolic aconitase, and whole cell superoxide production were 3 
unchanged. In isolated mitochondria, aconitase activity and hydrogen peroxide 4 
concentrations were also unchanged. In spite of this both whole cell and mitochondrial 5 
GSH:GSSG was lower. Taken together these data suggest that while overt oxidative 6 
stress does not exist, there is a degree of mild oxidative stress present in both 7 
mitochondria and whole homogenates. Use of two unique antioxidants (tempol and 8 
MnTBAP) allowed us to determine which ROS generating compartment was critical to 9 
the phenotype of cardiac hypertrophy. The fact that MnTBAP treatment lowered oxidized 10 
glutathione concentrations and improved GSH:GSSG in mitochondria without a 11 
concomitant reduction of cardiac hypertrophy, supports the conclusion that mitochondrial 12 
oxidative stress is not an important driver of the hypertrophy in G4H-/- mice. Tempol 13 
treatment, on the other hand, markedly attenuated hypertrophy. G4H-/- mice also 14 
displayed persistent translocation of p67phox (Figure 4) indicating activation of NOX2 and 15 
superoxide production. Given the importance of NOX2 as a major source of cytosolic 16 
oxidative stress and its role in cardiac hypertrophy [27-29], it is likely that NOX2 could be 17 
a cytosolic driver of cardiac hypertrophy in the G4H-/- mouse. However, tempol treatment 18 
did not alter the translocation of p67phox, nor were any changes in NOX activity observed 19 
by Ritchie et al[15, 30]. Taken together, these studies suggest that cytosolic sources of 20 
oxidative stress, rather than mitochondrial, are contributing to the hypertrophic 21 
phenotype, although neither our study nor that of Ritchie et al. have specifically 22 
elucidated the precise source of cytosolic ROS that mediates this effect.  23 
In spite of the reduction in hypertrophy after tempol treatment, whole cell 24 
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the lack of change in glutathione concentrations. 1) Either tempol exerts it action due to 1 
an off target or nonspecific effect that is unrelated to oxidative stress, or 2) glutathione 2 
concentrations in whole homogenates may not specifically reflect cytosolic glutathione 3 
concentrations. With regard to the latter point, whole cardiac tissue was homogenized to 4 
obtain GSH and GSSG concentrations. Mitochondria extracts present in this whole 5 
homogenate contributed to the levels of GSSG measured. It is possible that if the 6 
dosage of tempol used in this study did not successfully reduce mitochondrial GSSG 7 
levels, then the whole cell assay may reflect a GSH:GSSG concentration that is 8 
unchanged due to the contribution from the mitochondria. In support of this, it has been 9 
reported that tempol does not have a strong affinity for accumulating in mitochondria, 10 
and is only weakly reduced by the mitochondrial CoQ pool [31]. In contrast, mitoTempol, 11 
a mitochondrial targeted version of tempol, accumulates 100 fold greater in mitochondria 12 
and is strongly reduced by the mitochondrial CoQ pool [31]. Interestingly, there are other 13 
reports of i.v. tempol infusion failing to alter GSH:GSSG in skeletal muscle homogenates 14 
[32], and that at least 4 weeks of tempol treatment (1mM in drinking water) were required 15 
prior to improvement of GSH:GSSG in the heart. Thus a limitation of this study is the fact 16 
that we did not measure cytosolic levels of GSH and GSSG. 17 
 Since it was possible that tempol attenuated hypertrophy in G4H-/- mice through off 18 
target mechanisms that may be unrelated to oxidative stress, we examined two 19 
alternative mechanisms; GLUT1 expression and GSK3β activation. GLUT1 is a related 20 
and constitutively active glucose transporter. A compensatory increase in GLUT1 21 
expression could re-establish normal glucose supply and rescue the heart from GLUT4 22 
deficiency. Though we confirmed our previous findings that G4H-/- mice have an increase 23 
in GLUT1 expression [14], we did not find that tempol treatment increased GLUT1 24 
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reported to play a role in cardiac hypertrophy in other models of diabetes. For example, 1 
in diabetes produced by streptozotocin treatment, GSK3β is less phosphorylated (more 2 
active) in the hypertrophied heart of rodent models of diabetes [19]. Furthermore, when 3 
these rats are treated with tempol, the phosphorylation of GSK3β is increased, it 4 
becomes less active, and hypertrophy is subsequently reduced [19]. However, we did 5 
not observe any change in GSK3β activation in G4H-/- vs. Con mice, either before or 6 
after tempol treatment. In line with our data, Richie et al. found no change in GSK3β 7 
gene expression in hearts of mice with GLUT4 deletion superimposed on whole body 8 
GLUT4 suppression[15]. However, they also reported a significant increase in GSK3β 9 
expression following tempol treatment, whereas we saw no change. It is important to 10 
note that we assessed GSK3β status by measuring both total and phosphorylated 11 
GSK3β protein rather than changes in mRNA.  While we can speculate that GSK3β 12 
activation may be altered earlier in the development phase of hypertrophy (i.e. between 13 
4 and 7 weeks of age), our present data does not support a role for GSK3β in the G4H-/- 14 
mice. Another possible mechanism that could have mediated the observed reduction in 15 
cardiac hypertrophy in G4H-/- mice is reduction of blood pressure. A limitation of this 16 
study is that we did not measure blood pressure, however, it should be noted that there 17 
was no genetic manipulation of blood pressure regulating tissues such as arteries, 18 
kidneys, and brain, and that these mice had normal whole body metabolic profile, in spite 19 
of GLUT4 deletion in the heart. Therefore, we speculate that blood pressure was unlikely 20 
to be a factor.   21 
The G4H-/- mouse was originally developed to study the importance of insulin 22 
mediated glucose uptake in cardiac function [14]. As such the development of cardiac 23 
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our present study indicates that oxidative stress may contribute to the development of 1 
cardiac hypertrophy. While this notion has been confirmed by a previous study that used 2 
tempol to reduce hypertrophy in a different model of cardiac specific GLUT4 deletion that 3 
was superimposed on whole body GLUT4 suppression, the cellular source of ROS that 4 
drove hypertrophy remained elusive. In the present study, both the increased membrane 5 
translocation of p67phox and the efficacy of tempol to prevent hypertrophy suggest that 6 
the source of ROS in G4H-/- mice appears to be cytosolic. Furthermore, we demonstrate 7 
that improving mitochondrial redox state through the use of MnTBAP does not reduce 8 
hypertrophy. Therefore, the contribution of mitochondrial ROS to cardiac hypertrophy in 9 
cardiac specific GLUT4 deletion may be ruled out. 10 
 11 
MATERIALS AND METHODS 12 
 13 
Animals and methods for initial evaluation of markers of oxidative stress. 14 
 All protocols were approved by the University of Utah Institutional Animal Care 15 
and Use Committee. Mice with cardiac specific deletion of GLUT4 were generated as 16 
previously described (G4H-/-) [14]. Littermates with normal GLUT4 expression were used 17 
as controls (Con). Mixed cohorts of male and female mice were used for all studies since 18 
both develop cardiac hypertrophy as previously described [14]. All animals were kept on 19 
a 12 h light : dark cycle, and all experiments were conducted on random fed mice. Adult 20 
Con and G4H-/- mice (25±3 weeks old) were first used to determine status of markers of 21 
oxidative stress prior to conducting antioxidant treatment experiments.  22 
 23 
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Cardiac aconitase activity was measured in cytosolic fractions and isolated 1 
mitochondria as previously described using succinate as a metabolic substrate [33, 34].  2 
Aconitase activity has been previously shown to be sensitive to oxidative stress[34]. 3 
Assays were conducted in 50 mM Tris-HCl (pH 7.5) buffer containing 20 mM cis-aconitic 4 
acid. The rate of change of absorbance was followed for 10 min at 240 nm, with the 5 
activity expressed as mmol cis-aconitate used/min/mg of protein. 6 
 7 
Hydrogen peroxide concentrations. 8 
Mitochondrial H2O2 generation was measured as previously described [35, 36]. 9 
This method uses a spectro-fluorophotometer (RF5301PC; Shimadzu, Columbia, MD) 10 
that monitors H2O2-induced fluorescence of homovanillic acid (excitation wavelength 312 11 
nm, emission wavelength 420) in the prescence of horseradish peroxidase as a catalyst. 12 
Succinate (4 mmol/l) was used to stimulate ROS production after inhibition of the F1F0-13 
ATP synthase with oligomycin (1 µmol). Rotenone (10 µmol /L) was then added to the 14 
mixture to stop complex I–mediated superoxide production. Data is expressed as µmol / 15 
L / min / mg mitochondrial protein.  16 
 17 
Determination of reactive oxygen species. 18 
The presence of reactive oxygen species in cardiac homogenates were 19 
evaluated by using a method to measure the conversion of non-fluorescent 20 
dichlorodihydrofluorescein diacetate (DCFDA) to 2ʼ, 7ʼ – dichlorofluorescein (DCF) upon 21 
oxidation with free radicals [37]. Briefly, cardiac homogenates were prepared by 22 
homogenizing 50 mg of tissue in buffer containing 50 mM phospohate buffer, 1mM 23 
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pH 7.4 and centrifuging as previously described [36]. Both DCFDA and H2DCFDA were 1 
added to cardiac homogenates to achieve a 25μM final concentration. Excitation at 485 2 
nm and emission at 530 nm were then measured at 0 and 30 min at 37oC. Data is 3 
expressed as nmol DCF/mg protein/min. 4 
 5 
Measurement of cardiac malondialdehyde (MDA) concentrations. 6 
MDA concentrations were measured using LPO-586™ assay (Oxis Research, 7 
Portland, OR). Heart tissue was weighed and homogenized in 6 volumes of ice-cold 8 
phosphate-buffered saline (PBS, 20 mM, pH 7.4) containing 10 ml 0.5 M BHT in 9 
acetonitrile (to prevent sample oxidation during homogenization). After brief sonication, 10 
the homogenate was centrifuged at 3000 g at 4oC for 10 min and supernatant used to 11 
determine the concentration of MDA by incubating with 650 μl of diluted chromogenic 12 
reagent, N-methyl-2-phenylindole, at 45°C for 60 min. After incubation with the 13 
chromogenic agent, samples were centrifuged at 15,000 g for 10 min to obtain a clear 14 
supernatant in which absorbance at 586 nm was measured. Results are reported as 15 
nmol / g heart tissue used.  16 
 17 
Determination of glutathione concentrations in whole homogenates. 18 
Concentrations of oxidized (GSSG) and reduced (GSH) glutathione were 19 
determined using a kit from Oxis International (Foster City, CA), following the 20 
manufacturerʼs instructions. Both total GSSG and the ratio of GSH:GSSG was used as 21 
an index of oxidative stress. To determine whole heart GSH concentrations, 22 
approximately 25-35 mg of ventricular tissue was homogenized in 10 volumes of 5% ice 23 
cold metaphosphoric acid  (MPA). For measurement of GSSG, a similar sized heart 24 
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further oxidation of GSH to GSSG. All samples were done in duplicate and 1 
concentrations (nmol) of glutathione were normalized to ventricular tissue sample (g) 2 
used.  3 
 4 
Antioxidant treatments. 5 
Four-week old mice were given free access to water (Con; n=6, G4H-/-; n=7) or 6 
water with 1 mM tempol as previously described [15] (Con +T; n=7, G4H-/-+T n=7) for 4 7 
weeks. Previous studies have used a similar dosage of tempol in other models to 8 
successfully reduce oxidative stress [17, 38]. Water consumption was monitored daily 9 
during the treatment period to verify that the presence of tempol did not affect water 10 
intake. In a second experiment using an alternative antioxidant, 4-week old G4H-/- mice 11 
were treated every other day for 4 weeks with 10 mg/kg Mn(III) tetrakis (4-benzoic acid) 12 
porphyrin chloride (MnTBAP, i.p.) or saline-vehicle (Con + Veh; n=22, G4H-/-+ Veh; 13 
n=19, Con + MnTBAP; n=26, G4H-/-+ MnTBAP; n=23). At the end of both tempol and 14 
MnTBAP treatments, mice were anesthetized using chloral hydrate (90 mg/kg) and the 15 
heart was removed, rinsed and weighed. Hearts were then used to determine indices of 16 
oxidative stress from whole homogenates after tempol treatment or isolated 17 
mitochondria after MnTBAP treatments. 18 
 19 
Determination of mitochondrial glutathione concentrations after MnTBAP 20 
treatment. 21 
Freshly prepared mitochondria from individual hearts were isolated using STE1 22 
buffer (pH 7.4) [250mM sucrose, 5mM tris-HCl, and 2mM EGTA (Sigma-Aldrich, Inc., St. 23 
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MgCl2, 1mM ATP, and 2.5U/ml Sigma protease (Sigma-Aldrich, Inc., St. Louis, MO)] as 1 
previously described [39]. Ventricles were chopped in 4 ml ice-cold STE1 buffer 2 ~ 3 2 
times to wash out blood. After a 4-min digestion period in ice cold STE2, the digested 3 
tissue was washed in 5ml STE1 buffer and then homogenized on ice. Homogenates 4 
were centrifuged at 8,000g (4oC) for 10 minutes, re-suspended in 4 ml ice-cold STE1 5 
buffer, and centrifuged at 700g (4oC) for 10 minutes to separate mitochondria from other 6 
organelles. Finally, the supernatant (containing mitochondria) was centrifuged at 8,000g 7 
(4oC) for 10 minutes to wash out low-molecular weight impurities. 8 
To determine glutathione concentrations, fresh mitochondria were suspended in 9 
2.4 ml of ice-cold STE1 buffer, and aliquoted into 2 portions. Both aliquots were then 10 
centrifuged at 8000g (4oC), and the pellets recovered. For GSSG measurement, one 11 
aliquot was suspended in 0.45 volumes of ice-cold thiol- scavenger M2VP (Oxis 12 
International Inc., Portland, OR) plus 1.05 volumes of ice-cold 5% MPA (Sigma-Aldrich, 13 
Inc., St. Louis, MO). The other aliquot, used for determination of GSH, was suspended in 14 
2 volumes of ice-cold 5% MPA. Pellets were then snap frozen in liquid nitrogen and then 15 
stored under -140oC for later analysis using a kit from Oxis International (Foster City, 16 
CA), following the manufacturerʼs instructions. Mitochondrial GSH and GSSG 17 
concentrations (nmol) were normalized to mitochondrial protein (mg) content.  18 
 19 
Western blotting for p67phox protein expression after tempol treatment. 20 
Homogenization of hearts and western blotting was done as previously described 21 
[40, 41]. Antibodies directed against p67phox, a subunit of NADPH oxidase, were 22 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Signals were visualized by 23 
enhanced chemiluminescence (Cell Signal Technology, Beverly, MA). After exposure, 24 
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(GAPDH) as a loading control (Chemicon, Temecula, CA). Blots were prepared in 1 
triplicate and relative band densities were measured using a Kodak GL1500 gel imaging 2 
system.  3 
 4 
Real time PCR (RT-PCR) 5 
RNA extraction and quantitative RT-PCR was performed as previously described 6 
[42]. Total RNA was extracted from hearts with TRizol reagent (Invitrogen Corporation, 7 
Carlsbad, CA) and 3 µg of RNA were reverse transcribed using Superscript III Reverse 8 
Transcriptase (Invitrogen). Primers used for Brian Natiuretic Peptide (BNP), 9 
sarcoplasmic reticulum calcium ATPase (SERCA) 2a & 2b, α -myosin heavy chain (α-10 
MHC), β-myosin heavy chain (β-MHC), atrial natriuretic factor (ANF), glucose transporter 11 
1 (GLUT1), glutathione reductase (GR), glutathione peroxidase-1 (GPX1), glutathione 12 
peroxidase-4 (GPX4), thioredoxin-2 (TXN2), p47phox, and p67phox are shown in Table 4. 13 
The resulting cDNA were subjected to quantitative real-time RT-PCR. All reactions were 14 
performed in triplicate. Relative quantification was performed by interpolating crossing 15 
point data on an independent standard curve. Product size was confirmed by melting 16 
curve and agarose gel electrophoresis with ethidium bromide staining. Data were 17 
corrected for loading relative to the levels of the invariant transcript cyclophilin (Table 4) 18 
and normalized to GLUT4+/+ controls (a.u. = 1.0). 19 
 20 
Statistics 21 
 A t-test was used to detect significant differences in between control and G4H-/- 22 
mice during initial studies. A 2 way ANOVA (SPSS v.20) was used to determine 23 
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Bonferroni post-hoc test was used when main effects were detected after ANOVA. 1 
Significance was accepted at P<0.05. All data is expressed as mean±SEM. 2 
 3 
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Table 1. Morphology of 5 week old and 25 week old mice  1 
    Con    G4H-/-      2 
4 week old (n) 7 7 3 
Body weight (g)   16.4±1.0   14.1±1.1 4 
Heart weight (mg)  100±6    102±7 5 
Tibia length (mm)  15.34±0.26   14.65±0.46 6 
Heart : tibia (mg : mm) 6.51±0.31   6.94±0.36  7 
GSSG    13.2±1.4   20.0±2.8* 8 
GSH    798±38   887±44 9 
GSH:GSSG   62.0±5.8   45.5± 3.9*    10 
25 week old (n) 11 11  11 
Body weight (g)   28.7±1.6   27.8±1.7 12 
Heart weight (mg)  145±8    202±16* 13 
Tibia length (mm)  18.1±0.1   18.2±0.2 14 
Heart : tibia (mg : mm) 8.01±0.4   11.1±0.9*    15 
Data are mean ± SEM. Adult mice aged 4.9±0.5 and 25±3 weeks old. * Indicates 16 
significant differences at p<0.05. GSH and GSSG concentrations in 25-week-old cohort 17 
are shown in Figure 1. 18 
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Table 2. Tempol (1 mM) treated mice 1 
    Con  G4H-/-   Con + T G4H-/- + T   2 
n    15  13  16  16 3 
Body weight (g)  20.5±0.8 22.3±0.8 20.9±0.7 19.4±0.7 4 
Heart weight (mg)  110±4   146±5 * 110±4   121±6  5 
Tibia length (mm)  17.2±0.2 17.2±0.1 17.0±0.1 16.7±0.2 6 
Heart : tibia (mg : mm) 6.40±0.23  8.43±0.40 *  6.46±0.24  7.27±0.36  7 
Whole homogenate glutathione concentrations (nmol / g tissue) 8 
n    7  7  7  8 9 
GSH   799±34  634±36 * 604±27 * 598±31 * 10 
GSSG   11.1±1.6 13.5±1.0 9.9±2.6 12.7±2.0 11 
GSH:GSSG a  77±7  49±6   82±16   52±6  12 
              13 
Data are mean ± SEM. GSH, reduced glutathione. GSSG, oxidized glutathione. Con (Control), 14 
G4H-/- (Cardiac specific GLUT4 deletion), T = tempol. Mice were treated for 4 weeks, starting at 15 
age 4-weeks and studied at the age of 8±0 weeks. * Significant differences at p<0.05 vs. Con.  16 
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Table 3. MnTBAP (2 mg / kg) treated mice  1 
 Con G4H-/-  Con+MnTBAP G4H-/-+MnTBAP 2 
n 26 23 30  28 3 
Body weight (g) 21.2±0.6 20.4±0.6 21.3±0.5 21.0±0.5 4 
Heart weight (mg) 110±3  135±4 *  111±3  133±3 *  5 
n 17 17 19  22 6 
Tibia length (mm) 16.5±0.1 16.7±0.1 16.6±0.1 16.4±0.1 7 
Heart : tibia (mg : mm) 6.74±0.23  8.22±0.23 *  6.73±0.22  7.99±0.20 *  8 
Mitochondrial glutathione concentrations (nmol / mg mitochondrial protein) 9 
n 10 12 14  11 10 
GSH 712±36  604±40   730±34  646±38  11 
GSSG 19±3 34±3 *  16±3   23±3  12 
GSH:GSSG  40±3 22±4 *  48±3  31±4  13 
          14 
Data are mean ± SEM. GSH, reduced glutathione. GSSG, oxidized glutathione. Mice were treated 15 
for 4 weeks, starting at age 4-weeks and studied at the age of 8±0 weeks. * Significant differences 16 
at p<0.05 vs. Con. 17 
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Table 4. Primer pairs used for RT-PCR of selected genes in heart. 1 
 2 
Gene   Sequence (5ʼ - 3ʼ)     Product size (bp) 3 
 4 
BNP   GGATCTCCTGAAGGTGCTGT   205 5 
   TTCTTTTGTGAGGCCTTGGT 6 
 7 
SERCA2a  GAAACTACCTGGAACAACCCG   138 8 
   CTTTTCCCCAACCTCAGTCA 9 
 10 
SERCA2b  GAAACTACCTGGAACAACCCG   65 11 
   CGACAGGGAGCAGGAAGAT 12 
 13 
α-MHC  ACTGTGGTGCCTCGTTCC    276 14 
   TTCCGTTTTCAGTTTCCGC 15 
 16 
β-MHC  CATTCTCCTGCTGTTTCCTTAC   140 17 
   CATGGCTGAGCCTTGGAT 18 
 19 
ANF   ATGGGCTCCTTCTCCATCA    209 20 
   CCTGCTTCCTCAGTCTGCTC 21 
 22 
GLUT1  GCGGGAGACGCATAGTTACA   130 23 
   CTCCCACAGCCAACATGAG 24 
 25 
GPX1   GACTGGTGGTGCTCGGTT    151 26 
   TCACCATTCACTTCGCACTT 27 
 28 
GPX4   GCAGGAGCCAGGAAGTAATCAAGA  99 29 
   GCATCGTCCCCATTTACACA 30 
 31 
GR   GTGGCACTTGCGTGAATGTTG   60 32 
   GCACTGCTGTGTTCCACATTACCTT 33 
 34 
TXN2   GTGTGGGCTTCCCTCACCTCT   81 35 
   GGCTGGGCTGGGCATTACTGTTAGA 36 
   37 
p47phox  CCTGATGACCTGAAACTGCCCA   174 38 
   GGTTGCCACGGTCATCTCTGTT 39 
 40 
p67phox  GACTATCTGGGCAAGGCTACGGTT  69 41 
   AGGGGCGAAGCCAGAAAAGTTG 42 
 43 
Cyclophilin  AGCACTGGAGAGAAAGGATTTGG   349 44 
   TCTTCTTGCTGGTCTTGCCATT 45 
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Figure legends 1 
Figure 1. Indices of oxidative stress in whole homogenates and isolated mitochondria 2 
from hearts of cardiac specific GLUT4 deleted (G4H-/-) and control (Con) mice. All mice 3 
were 25±1 weeks old, except as indicated. A) Dichlorodihydrofluorescein diacetate 4 
(DCFDA) assay (nmol dichlorodihydrofluorescein (DCF) / mg protein/min), from mice 8.0 5 
±0.5 weeks old, G4H-/-; n= 8, Con; n=8. B) Mitochondrial hydrogen peroxide production 6 
(µmol / L / min / mg mitochondrial protein), G4H-/-; n= 6, Con; n=6. C) Malondialdehyde 7 
content (nmol / g heart), G4H-/-; n= 9, Con; n=7. D) Mitochondrial aconitase activity (nmol 8 
aconitase used / min / mg mitochondrial protein), G4H-/-; n= 6, Con; n=8. E) Cytosolic 9 
aconitase activity (nmol aconitase used / min / mg protein), G4H-/-; n= 9, Con; n=7. F) 10 
Reduced (GSH) glutathione (nmol / g heart), G4H-/-; n= 11, Con; n=10.  G) Oxidized 11 
(GSSG) glutathione (nmol / g heart), G4H-/-; n= 11, Con; n=10.  H) GSH : GSSG, G4H-/-; 12 
n= 11, Con; n=10. Data are mean ± SEM. * Indicates significant differences at p<0.05. 13 
Figure 2a, b, mRNA levels as determined by quantitative PCR in hearts of cardiac 14 
specific GLUT4 deleted (G4H-/-, n=7), control (Con, n=8), tempol treated G4H-/- (+T, n=8, 15 
1mM), and tempol treated Con mice (+T, n=9, 1mM). 2c, mRNA levels as determined by 16 
quantitative PCR in hearts of G4H-/- and Con mice treated with (Mn(III)tetrakis(4-Benzoic 17 
acid) porphyrin Chloride (+MnTBAP, 10 mg/kg, ip) or Vehicle (+Veh, saline), n=4 for 18 
each group. All samples are normalized to cyclophilin expression and normalized to 19 
controls. Data are mean ± SEM. * Indicates significant differences at p<0.05. vs. Con.  20 
Figure 3a. Glutathione peroxidase 4 (GPX4) and glutathione reductase (GR) protein 21 
levels in hearts of cardiac specific GLUT4 deleted (G4H-/-, n=7), control (Con, n=8) mice, 22 
tempol treated G4H-/- (+T, n=8, 1mM), and tempol treated Con mice (+T, n=9, 1mM). 3b. 23 
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(Mn(III)tetrakis(4-Benzoic acid) porphyrin Chloride (+MnTBAP, 10 mg/kg, ip, n=5) or 1 
Vehicle (+Veh, saline, n=4). Data are mean ± SEM. * Indicates significant differences at 2 
p<0.05. vs. Con. 3 
Figure 4. p67phox protein levels in membrane fractions of cardiac homogenates from 4 
cardiac specific GLUT4 deleted (G4H-/-, n=7), control (Con, n=7) mice, tempol treated 5 
G4H-/- (+T, n=8, 1mM), and tempol treated Con mice (+T, n=7, 1mM). IR, insulin 6 
receptor, used as loading control for membrane bound proteins. Data are mean ± SEM. * 7 
Indicates significant differences at p<0.05 vs. Con.  8 
Figure 5. Glycogen synthase kinase 3β (GSK) and phospho (p)-GSK3 β protein levels 9 
in hearts of cardiac specific GLUT4 deleted (G4H-/-, n=7), control (Con, n=8) mice, 10 
tempol treated G4H-/- (+T, n=8, 1mM), and tempol treated Con mice (+T, n=9, 1mM). 11 
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